Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.54 |
| ▸ | CDK1 | P06493 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.54 |
| ▸ | MARK3 | P27448 | 2/20 | 0.54 |
| ▸ | BLK | P51451 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.54 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.54 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27770482 | 1.00 | MAP3K5 (0.60) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| SCHEMBL31381352 | 1.00 | MAP3K5 (0.60) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| Benzene SCHEMBL28188863 | 1.00 | MAP3K5 (0.60) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| SCHEMBL4573935 | 0.98 | MAP3K5 (0.58) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| Hydrochloric Acid SCHEMBL8807679 | 0.98 | MAP3K5 (0.58) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| Quinoline SCHEMBL28107595 | 0.90 | ALDH1A1 (0.53) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| SCHEMBL6467426 | 0.88 | MAP3K5 (0.54) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| SCHEMBL3338544 | 0.86 | AURKA (0.57) | MAP3K5ROCK1CDK2CDK1GSK3B | |
| SCHEMBL3339632 | 0.86 | NPY5R (0.55) | MAP3K5ROCK1CDK2CDK1AURKA | |
| SCHEMBL6037487 | 0.86 | ROCK1 (0.53) | MAP3K5ROCK1CDK2CDK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 814 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | claimed |
| WO-2023240271-A1 | USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY | FOUNTAIN THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | claimed |
| CN-114831992-B | Application of anilinoquinazoline compound in preparation of medicines for preventing or treating melanoma | 浙江工业大学 | 2023-07-11 | — | — | CN | claimed |
| CN-114831992-A | Application of phenylamino quinazoline compound in preparation of drugs for preventing or treating melanoma | 浙江工业大学 | 2022-08-02 | — | — | CN | claimed |
| CN-109942500-B | Preparation of rhein anilino quinazoline derivatives and anti-tumor application | 广西医科大学 | 2022-06-10 | — | — | CN | claimed |
| CN-111808117-B | Artemisinin-anilino quinazoline D-type derivative, and pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2022-05-24 | — | — | CN | claimed |
| US-11279982-B2 | EGFR assay | ABBOTT MOLECULAR INC. (US) | 2022-03-22 | — | — | US | claimed |
| CN-108484632-B | Artemisinin-anilinoquinazoline derivatives, and preparation method and application thereof | 中国科学院昆明植物研究所 | 2021-09-10 | — | — | CN | claimed |
| CN-111518088-B | Preparation method and application of aniline quinazoline intermediate | 山东创新药物研发有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-111808117-A | Artemisinin-anilinoquinazoline D-type derivative, and pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2020-10-23 | — | — | CN | claimed |
| WO-2005063252-A1 | CDK2 ANTAGONISTS AS SHORT FORM C-MAF TRANSCRIPTION FACTOR ANTAGONISTS FOR TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2005-07-14 | — | — | WO | claimed |
| WO-2005053752-A2 | NOVEL IMAGING AGENTS COMPRISING CASPASE-3 INHIBITORS | GE HEALTHCARE LIMITED (GB) | 2005-06-16 | — | — | WO | claimed |
| WO-2005037259-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NEOPLASIA COMPRISING A COX-2 INHIBITOR IN COMBINATION WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2004069232-A2 | EGFR TYROSINE KINASE INHIBITOR FOR TREATING CARDIOVASCULAR DYSFUNCTION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2004-08-19 | — | — | WO | claimed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | claimed |
| EP-1432816-A2 | USE OF ACTIVE SUBSTANCES FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISEASES CAUSED BY CELL GROWTH DISTURBANCES AND TEST SYSTEM FOR DISCOVERY OF SAID ACTIVE SUBSTANCES | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2004-06-30 | — | — | EP | claimed |
| WO-2003027317-A2 | USE OF ACTIVE SUBSTANCES FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISEASES CAUSED BY CELL GROWTH DISTURBANCES AND TEST SYSTEM FOR DISCOVERY OF SAID ACTIVE SUBSTANCES | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2003-04-03 | — | — | WO | claimed |
| WO-2001035899-A9 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-09-19 | — | — | WO | claimed |
| EP-1229925-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001035899-A2 | INHIBITORS OF HELICOBACTER PYLORI INDUCED GASTROINTESTINAL DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2001-05-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | MAP3K5 239/4885ROCK1 789/4885CDK2 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.